Zacks Investment Research lowered shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a buy rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
A number of other research firms also recently weighed in on APTO. HC Wainwright set a $9.00 target price on Aptose Biosciences and gave the stock a buy rating in a report on Monday, November 26th. B. Riley started coverage on Aptose Biosciences in a report on Friday, November 16th. They set a buy rating and a $5.00 target price for the company. Finally, Roth Capital reissued a buy rating on shares of Aptose Biosciences in a report on Wednesday, December 12th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $5.63.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03. On average, equities analysts predict that Aptose Biosciences will post -0.87 EPS for the current year.
An institutional investor recently bought a new position in Aptose Biosciences stock. Citadel Advisors LLC purchased a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 48,239 shares of the biotechnology company’s stock, valued at approximately $125,000. Citadel Advisors LLC owned approximately 0.13% of Aptose Biosciences as of its most recent SEC filing. 3.28% of the stock is owned by hedge funds and other institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also: Stochastic Momentum Index (SMI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.